Pfizer Inc. (NYSE:PFE – Get Free Report) shares rose 1.3% during mid-day trading on Tuesday . The stock traded as high as $25.96 and last traded at $25.6640. Approximately 40,929,096 shares changed hands during mid-day trading, a decline of 3% from the average daily volume of 42,348,012 shares. The stock had previously closed at $25.33.
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer announced strong Phase 2 results for its investigational 25-valent pneumococcal vaccine in infants, including a stronger immune response than Prevnar 20 and up to 15-fold higher antibody levels against a key strain. The company is now moving the program into pivotal Phase 3 testing, which could support future vaccine growth. Article Title
- Positive Sentiment: The company also received a broader European indication for HYMPAVZI, adding another recent R&D win that may strengthen Pfizer’s hemophilia franchise and improve investor confidence in the pipeline. Article Title
- Positive Sentiment: Pfizer and Rigel Pharmaceuticals expanded a commercialization deal for VEPPANU (vepdegestrant), creating another potential partnership-driven revenue stream tied to oncology. Article Title
- Positive Sentiment: Pfizer’s oncology growth story is also getting attention, with coverage pointing to Padcev, biosimilars, and late-stage pipeline assets as key long-term drivers. Article Title
- Neutral Sentiment: Pfizer was also listed as a participant in an AI industry summit, but this appears unrelated to the company’s core investment thesis and is unlikely to move the stock on its own. Article Title
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. BMO Capital Markets reissued an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. UBS Group increased their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a report on Monday, April 13th. Citigroup increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. HSBC increased their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Finally, CICC Research assumed coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.61.
Pfizer Stock Up 0.5%
The firm’s 50-day moving average price is $26.88 and its 200 day moving average price is $26.23. The firm has a market cap of $147.76 billion, a P/E ratio of 19.79 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.
Hedge Funds Weigh In On Pfizer
Institutional investors have recently modified their holdings of the company. Essential Partners LLC grew its position in Pfizer by 19.8% in the 1st quarter. Essential Partners LLC now owns 4,381 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 724 shares in the last quarter. Vestor Capital LLC grew its position in Pfizer by 150,540.9% in the 1st quarter. Vestor Capital LLC now owns 680,897 shares of the biopharmaceutical company’s stock valued at $19,120,000 after buying an additional 680,445 shares in the last quarter. Arete Wealth Advisors LLC grew its position in Pfizer by 4.8% in the 1st quarter. Arete Wealth Advisors LLC now owns 119,492 shares of the biopharmaceutical company’s stock valued at $3,352,000 after buying an additional 5,505 shares in the last quarter. SOA Wealth Advisors LLC. grew its position in Pfizer by 16.8% in the 1st quarter. SOA Wealth Advisors LLC. now owns 7,472 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 1,074 shares in the last quarter. Finally, Leigh Baldwin & CO. LLC grew its position in Pfizer by 2.3% in the 1st quarter. Leigh Baldwin & CO. LLC now owns 19,788 shares of the biopharmaceutical company’s stock valued at $556,000 after buying an additional 452 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
